Home > Press > Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
Abstract:
Altogen Biosystems (
www.altogen.com) announced launch of novel Nanoparticle-based transfection reagent for use in laboratories and research facilities for animal testing. Transfection is one of the major laboratory methods used to introduce DNA and RNA molecules into cells and tissues. This technique makes it possible to cross the cellular barriers and deliver a gene or a small interfering RNA (siRNA) into the cells for research or therapeutic purposes.
Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
LAS VEGAS, NV | Posted on November 4th, 2008
The company has previously developed lipid- and polymer-based in vivo transfection reagents (www.altogen.com/mirna.htm) used for testing pharmaceuticals in animals. Altogen Biosystems recently developed novel nanoparticles biotechnology that allows highly efficient delivery of various biomolecules into animal tissues via systemic administration, as well as intraperitoneal and direct intratumoral injections.
Altogen Biosystems is focusing on commercializing pharma- and bio-technologies, as well as providing custom laboratory research services. The company now offers such innovative services as generation of stably-transformed cell lines in 28-days, as well as gene silencing and RNAi services (www.altogen.com/support.htm).
####
About Altogen Biosystems
Altogen Biosystems is a life sciences company located in Las Vegas, Nevada. The company is dedicated to the engineering, marketing and manufacture of transfection reagents and kits for intracellular and tissue-targeted delivery of biomolecules (www.altogen.com).
Altogen Custom Services focus on providing specialized biotechnology and pharmaceutical services, including generation of stable cell lines, gene silencing and RNA Interference (RNAi) services, assay development, library screening, and transfection services (www.altogen.com/support.htm).
For more information, please click here
Contacts:
Andreas Kim
Altogen Biosystems
+1-512-350-0302
Copyright © PR Newswire Association LLC.
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
News and information
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
Beautiful "flowers" self-assemble in a beaker: Elaborate nanostructures blossom from a chemical reaction perfected at Harvard May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013
Nanomedicine
Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013
Announcements
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013